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 Inhibition of MAPK signaling promotes cell cycle arrest and sensitizes 
intrahepatic cholangiocarcinoma cells to chemotherapy. 
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Introduction and Aim: Intrahepatic cholangiocarcinoma (ICC) is the second most 
common primary hepatic malignancy, accounting for approximately 15% of cases of 
primary liver cancer. Although new treatments have increased survival for many 
other cancers, including the more common primary hepatocellular carcinoma, 
treatment strategies and survival for patients with ICC have seen little improvement. 
Our previous studies suggest that the mitogen-activated protein kinase (MAPK) 
signaling plays a central role in the regulation of cell proliferation in human ICC. 
However the molecular mechanisms are poorly understood. In this study, we aim to 
explore whether chemical inhibition of the MAPK pathway and its downstream 
effectors enhances the sensitization of ICC cells to the chemotherapeutic agent 
cisplatinum.  
Methods: We used a combinatorial approach of immunohistochemical and gene 
expression analyses of microarray datasets to investigate the expression of MAPK-
related genes in ICC tumors. Furthermore, by using in-vitro and in-vivo analyses we 
have characterized the function of a novel MAPK downstream effector in ICC cells.  
 
Results: The expression of MAPK signaling was determined by 
immunohistochemical staining in tumor samples from a cohort of 14 ICC patients. 
High expression of phospho-activated MAPK was observed in 71.4% (10/14) of ICC 
cases as compared with surrounding nontumor tissue. Likewise, expression of JDP, 
a downstream effector of the MAPK signaling, was scored as high intensity in 64.3% 
(9/14). Strikingly, elevated expression of JDP transcripts was also observed in two 
independent cohorts of human ICC (n=149 and n=109 per group, respectively) 
compared to surrounding normal liver tissue. Consistent with the in-vivo analyses of 
human samples, immunoblotting analyses showed constitutive activation of MAPK 
and expression of JDP in ICC-derived cells (i.e. SG231, CCLP-1 and HuCCT1). 
Using loss-of-function analyses, we demonstrates that knockdown of JDP in ICC-
derived cells resulted in cell cycle arrest and reduced expression of cell cycle 
regulators (i.e. cyclin D1, cyclin E), and had minimal effect on apoptosis. Chemical 
inhibition of JDP significantly sensitizes ICC-derived cells to cisplatinum 
(***P<0.0001). 
 
Conclusions: These results demonstrate that enhanced activation of MAPK 
signaling is important for ICC cell proliferation and suggest that targeting its 
downstream effectors is a potential therapeutic strategy for ICC.  
 
 
 
